Similarly, alternative combination therapy for HER2-negative BC of docetaxel and cyclophosphamide (TC) was assessed by Caparica and collaborators in a meta-analysis, compared six cycles of this combined therapy versus an anthracycline and taxane-based regimen (A + T) in the adjuvant treatment of HER2-negative BC. Here, ERBB2 is linked to breast cancer.